LS@W supports Life Sciences startups through the Venture Challenge, Expert Classes and Value Center programs. Startups that have participated in (one or more) of these programs are listed as LS@W alumni. In addition startups that have received an NGI Pre-Seed Grant, which was part of LS@W from 2007 - 2012, are listed as LS@W alumni.
The Venture Challenge is the most successful program for startups in the Life Sciences and Medical Technology. More than 25 editions of the Venture Challenge have been organised helping startups in Therapeutics, Diagnostics, Medical Devices and Enabling Technologies. Startups that have participated in the Venture Challenge and still exist are listed.
Pre-Seed Grant Alumni
In the first years of LifeSciences@Work the NGI Pre-Seed Grant was part of the program. Startups that have received a Pre-Seed Grant via the LS@W program and still exist are listed.
OcellO offers in vitro assays which recapitulate and quantify complex human biology in a robust and high-throughput format.
We test compounds for oncology, immuno-oncology, inflammation and cystopathy indications.
Panorama Laboratories is building a new class of lab devices. Instead of measuring characteristics of samples, we measure characteristics of protocols while they are being executed. These devices will allow for instant and objective documentation of high impact actions in the lab.
Easy & accurate long-term monitoring for Atrial Fibrillation. By providing unobtrusive, long-term monitoring and reliable diagnosis, Praxa Sense offers a solution to detect heart rhythm diseases in an early stage, preventing up to 9 strokes each day in The Netherlands alone.
We developed a test that accurately identifies patients that will develop rheumatoid arthritis within 3 years. Our mission is to substantially reduce the high burden of this disease by helping rheumatologists worldwide identify these high-risk patients in order to start preventive therapy.
Predica’s mission is to personalize the population based screening program cervical cancer and thereby prevent overdiagnosis and unnecessary treatment of healthy women who test positive in the current screening program.
Prolira provides the first proprietary and validated biomarker-based medical device to detect the onset of delirium, with a sensitivity of 90%. This enables health care professionals in realising better patient outcome, saving hospital days and reducing costs.